Hepatitis C virus
infection (HCV), one of the greatest causes of
liver disease, is a frequent complication in patients with
end-stage renal disease (
ESRD) on dialysis.
ESRD is defined as decreased glomerular filtration and also accompanied by impaired function of the immune system.
Galectin-3 is a β-galactoside-binding
lectin, involved in various biological processes including pathogenesis of
chronic renal disease. The aim of our study was to estimate disease severity in
ESRD HCV+ patients and analyze the serum concentrations of IL-1β,
IL-4,
IL-23, and IL-6;
anti-HCV antibodies; and
galectin-3. Also, we attempted to determine potential correlation between
galectin-3 level and parameters of disease severity ALT and AST. Our results showed decreased levels of ALT and AST (p = 0.00), demonstrating less liver destruction in
ESRD HCV+ patients in comparison to HCV+ patients. Increased levels of
IL-6 (p = 0.03) implicate a hepatoprotective role of
IL-6 in these patients. Also, level of
galectin-3 (p = 0.00) in the serum of
ESRD HCV+ patients was higher than that of HCV+ patients. This alteration was accompanied with negative correlation between
galectin-3 and AST and ALT, respectively (p = 0.029; p = 0.033). The presence of increased systemic levels of
IL-6 and Gal-3 in
ESRD HCV+ patients may be an attempt to counteract or limit ongoing proinflammatory processes and to downregulate chronic
inflammation, suggesting the new aspects of HCV
infection in
ESRD patients.